1. Home
  2. MYGN

as of 11-20-2026 3:45pm EST

$5.44
$0.11
-1.98%
Stocks Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances Nasdaq

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Founded: 1991 Country:
United States
United States
Employees: 2700 City: SALT LAKE CITY
Market Cap: 523.7M IPO Year: 1996
Target Price: $5.90 AVG Volume (30 days): 1.7M
Analyst Decision: Hold Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.28 EPS Growth: -180.14
52 Week Low/High: $2.74 - $8.09 Next Earning Date: 11-04-2026
Revenue: $771,400,000 Revenue Growth: 2.33%
Revenue Growth (this year): -4.66% Revenue Growth (next year): -8.43%
P/E Ratio: -4.34 Index:
Free Cash Flow: -43500000.0 FCF Growth: N/A

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 4, 2026 · 100% conf.

AI Prediction SELL

1D

-13.65%

$5.22

Act: +4.98%

5D

-16.69%

$5.03

20D

-16.22%

$5.06

Price: $6.04 Prob +5D: 0% AUC: 1.000
0001628280-26-070135

EX-99.1

2 ex991mygn-xearningsrelease.htm

EX-99.1

Document

Exhibit 99.1

Myriad Genetics Reports Third Quarter 2026 Financial Results;

Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution

Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives

Highlights

•Third quarter 2026 revenue was $202.7 million, representing a 6% sequential increase and a 1% decrease year-over-year. Higher Cancer Care Continuum (CCC) product mix and continued progress on payer engagement and revenue cycle management initiatives drove total average revenue per test increases of 7% sequentially and 1% year-over-year, partially offset by total test volume declines of 1% and 2%, respectively.

•On October 19, 2026, entered into a definitive agreement to sell the Prenatal Health business to Labcorp for $210 million in cash, plus the value of related inventory at closing. Upon close, the sale is expected to be accretive to revenue growth and profitability, while strengthening the balance sheet.

•Raises mid-point of full-year 2026 revenue guidance to reflect third quarter 2026 results and current business trends for the remainder of 2026.

SALT LAKE CITY, November 4, 2026 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2026, and raised the mid-point of revenue guidance for the full-year 2026.

1

“We have made meaningful progress on our path to accelerate profitable growth and strengthen the company’s financial profile. Our third quarter 2026 financial results exceeded our expectations, led by our on-going focus on the Cancer Care Continuum (CCC).  Average revenue per CCC test in the third quarter 2026 was higher than in the second quarter 2026 and reflects our team's ongoing work and early progress with payer engagement and revenue cycle management initiatives," said Sam Raha, President and CEO, Myriad Genetics. “The sale of our Prenatal Health business is a decisive step to support our strategic intent to increase profitable growth by focusing on the Cancer Care Continuum including screening, treatment selection and monitoring along with remission surveillance. We expect this action to benefit healthcare providers and patients we serve, as well as our employees and shareholders, and improve Myriad's revenue growth rate, profitability, and liquidity going forward.  Lastly, we are increasing the mid-point of our full-year 2026 revenue guidance modestly, as we balance the positive third quarter 2026 performance with the timing of the sale of the Prenatal Health business, which is expected to close by early 2027."

Financial and Operational Highlights

•Third quarter 2026 test volume for Cancer Care Continuum and Mental Health increased 3% year-over-year to 239,000 tests, while Prenatal Health test volume decreased 11% to 138,000 tests, reflecting ongoing trends in the business, which the Company recently announced it plans to divest.

•Third quarter of 2026 average revenue per test increased 1% year-over-year reflecting product mix and incremental progress with payer engagement and revenue cycle management initiatives.

2

•The following table summarizes year-over-year testing volume changes in the company's core product categories:

Three months ended September 30,Nine months ended September 30,

(in thousands)20262025% Change20262025% Change

Product volumes:

Cancer Care Continuum98 94 4 %289 269 7 %

Mental Health141 137 3 %417 399 5 %

Cancer Care Continuum and

Mental Health Volume* 239 231 3 %706 668 6 %

Prenatal Health138 155 (11)%435 487 (11)%

Total377 386 (2)%1,141 1,155 (1)%

•The following table summarizes year-over-year revenue changes in the company's core product categories:

Three months ended September 30,Nine months ended September 30,

(in millions) 20262025% Change20262025% Change

Product revenues:

Cancer Care Continuum$123.9 $122.5 1 %$358.2 $365.8 (2)%

Mental Health39.5 38.72 %114.6 107.5 7 %

Cancer Care Continuum and

Mental Health Revenue* 163.4 161.21 %472.8 473.3— %

Prenatal Health39.3 44.5(12)%121.0 141.4 (14)%

Total$202.7 $205.7 (1)%$593.8 $614.7 (3)%

*

On October 19, 2026, the Company entered into a definitive agreement to sell certain assets and liabilities of its Prenatal Health business. A Cancer Care Continuum and Mental Health volume and revenue subtotal is presented to provide additional information regarding the revenue of the businesses expected to remain with the Company following completion of the sale, which is expected to close by early 2027.

Product Categories:

Cancer Care Continuum – MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris + AI, Precise Tumor, Precise MRD

Mental Health – GeneSight

Prenatal Health – Foresight, Prequel, FirstGene, SneakPeek

•Third quarter 2026 gross margin was 67.9%, down 200 basis points from the third quarter 2025, reflecting lower overall test volumes and incre

2026
Q2

Q2 2026 Earnings

8-K SELL

Jul 30, 2026 · 100% conf.

AI Prediction SELL

1D

-10.87%

$4.79

Act: -46.93%

5D

-14.68%

$4.58

20D

-14.17%

$4.61

Price: $5.37 Prob +5D: 0% AUC: 1.000
0000899923-26-000070

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1785586584.2f1220a0

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2026
Q1

Q1 2026 Earnings

8-K SELL

May 5, 2026 · 100% conf.

AI Prediction SELL

1D

-10.20%

$4.52

Act: -18.29%

5D

-14.28%

$4.31

Act: -19.09%

20D

-14.32%

$4.31

Act: -12.52%

Price: $5.03 Prob +5D: 0% AUC: 1.000
0000899923-26-000036

EX-99.1

2 ex991mygn-xearningsrelease.htm

EX-99.1

Document

Exhibit 99.1

Myriad Genetics Reports First Quarter 2026 Financial Results;

Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

Highlights

•First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test.

•First quarter 2026 test volume reflects 13% and 7% test volume growth year-over-year in Cancer Care Continuum and Mental Health, respectively, offset by a 12% decline year-over-year in Prenatal Health test volume.

•Launched Precise Molecular Residual Disease (MRD), Myriad Genetics' ultrasensitive assay, representing progress toward earlier insight, more informed decisions, and better outcomes for cancer patients.

•Received FDA approval of the MyChoice CDx test as the companion diagnostic for Zejula®, for patients with advanced ovarian cancer.

•First quarter 2026 gross margin was 68.7%, up 20.0 basis points from the first quarter 2025.

•First quarter 2026 GAAP net loss of $34.1 million, or $0.36 per share, while adjusted loss per share was $0.09 per share and adjusted EBITDA was $(4.5) million.

SALT LAKE CITY, May 5, 2026 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its first quarter ended March 31, 2026, and reaffirmed its financial guidance for the full-year 2026.

"We are seeing strong performance across a number of key areas, including the Cancer Care Continuum as we begin to realize a return on our focused strategy. We have implemented a dedicated hereditary cancer sales force and other key programs designed to support the expected continued growth in germline testing. And with decisive steps taken to address our Prenatal Health business, we expect improved performance in the remainder of 2026,” said Sam Raha, President and CEO, Myriad Genetics. “Our limited launch of Precise MRD for breast cancer patients has received positive early feedback and we remain on track with our other planned launches in 2026, as part of our milestone-rich year. We are confident these tests will be important drivers of our growth in 2027 and beyond."

1

Financial and Operational Highlights

•Test volumes of 385,000 in the first quarter of 2026 were stable year-over-year.

•The following table summarizes year-over-year testing volume changes in the company's core product categories:

Three Months Ended March 31,

(in thousands)20262025% Change

Product volumes:

Cancer Care Continuum96 85 13 %

Prenatal Health153 173 (12)%

Mental Health136 127 7 %

Total385 385 — %

•The following table summarizes year-over-year revenue changes in the company's core product categories:

Three Months Ended March 31,

(in millions) 20262025% Change

Product revenues:

Cancer Care Continuum$120.2 $115.6 4 %

Prenatal Health41.9 49.3 (15)%

Mental Health38.3 31.0 24 %

Total$200.4 $195.9 2 %

Product Categories:

Cancer Care Continuum – MyRisk, BRACAnalysis CDx, MyChoice CDx, Prolaris, Precise Tumor, Precise MRD

Prenatal Health – Foresight, Prequel, FirstGene, SneakPeek

Mental Health – GeneSight

•Operating expenses in the first quarter of 2026 were $168.3 million, increasing $5.1 million year-over-year. Adjusted operating expenses in the first quarter of 2026 increased $7.9 million year-over-year to $148.5 million, partially reflecting the company's progress in its multi-year investment program in key strategic areas.

•Operating loss in the first quarter of 2026 was $30.7 million.

Cash Flow and Liquidity

First quarter 2026 cash flow used in operations was $15.7 million; adjusted operating cash outflow in the first quarter of 2026 was $13.4 million. Capital expenditures and capitalization of internal use software costs totaled $6.5 million in the first quarter 2026 resulting in adjusted free cash flow of $(19.9) million in the first quarter of 2026.

As of the end of the first quarter of 2026, the company had cash and cash equivalents of $124.4 million.

2

Business Performance and Highlights

Cancer Care Continuum

The Cancer Care Continuum business delivered revenue of $120.2 million in the first quarter of 2026.

•First quarter 2026 hereditary cancer testing revenue increased 5% year-over-year driven by a 14% year-over-year increase in volume.

•First quarter 2026 Prolaris testing revenue grew 3% year-over-year. The company continues to make progress on its first AI-enabled prostate cancer test, in partnership with PATHOMIQ, and expects to launch the test in the second quarter of 2026.

•In April 2026, the company shared new data at a number of annual clinical society meetings, including the American Association for Cancer Research (AACR) and the Society of Gynecologic Oncology (SGO) underscoring Myriad Genetics' commitment to the Cancer Care Continuum and highlighting its progress in precision oncology. For example, data from one

Share on Social Networks: